Amal Saidi

Amal Saidi has been the Head of Preclinical Research of Orano Med since 2023.  Amal's journey in nuclear medicine began after completing her thesis in Germany and post-doctoral work in England. She initially joined Roche, where she embraced the challenge of working in nuclear medicine. Her results led her to Orano Med, where she has continued to make significant contributions to oncology research. Her primary work focuses on developing targeted alpha therapy to fight cancer, specifically using the radioisotope lead-212 to destroy cancer cells while minimizing damage to surrounding healthy tissues.

Amal Saidi holds a Doctorate in Genetics obtained from the University of Jena.